在过去10年里,萨尔科佩尼亚和癌症的全球趋势:图书统计分析
Ruoshuang Liu1, Menghuan Wu2, Xia Cheng3
1Department of Endocrinology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Discover oncology
|July 17, 2025
概括
癌症患者常见的担忧是萨尔科佩尼亚. 本文库分析回顾了过去十年的研究趋势,突出了萨尔科佩尼亚和癌症研究的关键主题和未来方向.
科学领域:
- 在瘤学瘤学.
- 老年病的医生 老年病的医生
- 生物医学研究生物医学研究
背景情况:
- 癌症患者中常见的是肉症 (与年龄相关的肌肉损失).
- 癌症及其治疗加剧了肌肉损失.
- 了解研究趋势对于推进医疗保健至关重要.
研究的目的:
- 分析癌症中萨尔科佩尼亚的研究状态.
- 确定该领域的新兴趋势.
- 为未来的研究方向提供参考资料.
主要方法:
- 从2014年到2023年对出版物的图书统计分析.
- 数据来源于科学网络数据库的数据.
- 使用了包括VOSviewer,CiteSpace和R包"Bibliometrix"在内的可视化工具.
主要成果:
- 分析了3749篇出版物,涉及来自76个国家的21,507名作者.
- 日本,美国和中国是主要的贡献者.
- 关键的研究主题包括:sarcopenic肥胖症,放射性,以及中性粒细胞/淋巴细胞比率.
结论:
- 这是对萨尔科佩尼亚和癌症文献的首次图书统计分析.
- 该研究系统地概述了当前的研究和未来的趋势.
- 这些发现为该领域的研究人员提供了宝贵的见解.
相关概念视频
Cancer Survival Analysis
456
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
456
Changes in the Appendicular Skeleton with Age
2.3K
The upper and lower limb initially develops as a small bulge called a limb bud, which appears on the lateral side of the early embryo. The upper limb bud appears near the end of the fourth week of development, with the lower limb bud appearing shortly after.
Initially, the limb buds consist of a core of mesenchyme covered by a layer of ectoderm. The ectoderm at the end of the limb bud thickens to form a narrow crest called the apical ectodermal ridge. This ridge stimulates the underlying...
Initially, the limb buds consist of a core of mesenchyme covered by a layer of ectoderm. The ectoderm at the end of the limb bud thickens to form a narrow crest called the apical ectodermal ridge. This ridge stimulates the underlying...
2.3K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Rous Sarcoma Virus (RSV) and Cancer
5.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.4K
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K


